Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? - Wikidata - wikimedia - TriplyDB

Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

http://www.wikidata.org/entity/Q34480557

about

Aberrant expression of interleukin-1β and inflammasome activation in human malignant gliomas Sui generis: gene therapy and delivery systems for the treatment of glioblastoma Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials Targeting immune checkpoints in malignant glioma Prospects of immune checkpoint modulators in the treatment of glioblastoma Immunocompetent murine models for the study of glioblastoma immunotherapy Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma.Differential glioma-associated tumor antigen expression profiles of human glioma cells grown in hypoxia.Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours Immunotherapy for malignant glioma B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Recent developments on immunotherapy for brain cancer.Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial Down-regulation of IKKβ expression in glioma-infiltrating microglia/macrophages is associated with defective inflammatory/immune gene responses in glioblastoma.Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.Consequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptoms Advances in Immunotherapy for Glioblastoma Multiforme.Evolution of care for patients with relapsed glioblastoma.Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas.Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.Immunotherapy for the treatment of glioblastoma.CNS macrophages and peripheral myeloid cells in brain tumours.Vaccine-based immunotherapy for glioblastoma.Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.Current challenges in designing GBM trials for immunotherapy.Immunotherapeutic advancements for glioblastoma.Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression.Immune Checkpoint Inhibitors in Gliomas.Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells.Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.The taxonomy of brain cancer stem cells: what's in a name?Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.

P2860

Q24810414-0C7272AD-4B17-4DD3-9106-975B1C4CFFD3 Q26850467-83638ABC-153C-49C1-9DF8-CB27D07FB8E2 Q27014829-81E47765-CA84-4B65-95AC-27E7C13C01EF Q28072012-4786ED5D-12DD-49AE-9FA9-078D5D532299 Q28081371-3A6FFD0C-C099-4C0B-AED9-C1130E7538D2 Q33574853-3960E749-1543-4A81-8BB0-3D9693312D98 Q33800747-4AC5EE92-F7E2-43E3-8067-34329492D1BE Q33999299-C8BB4487-B496-4546-B674-E9060FA9357F Q34407938-EDD28AE8-AF48-4117-B996-75535E66C54F Q34596741-F451DBBD-C0D5-42CC-967F-0D265BE636A5 Q34744875-7BABDDB7-C693-4A09-8CCE-96D42E9C8499 Q35114086-B95C46EF-787A-4DEA-A132-6BDC6731AA59 Q35444346-644FEEAF-9C14-4865-97E7-70B9EB64FBF5 Q35799695-74D84950-C80F-42F4-B185-2C8C442B8B0C Q35992355-8AAE3DD2-25FB-4AAA-A483-16F817DC9E12 Q36345439-7A378231-E0E1-4BA5-AB70-032089DD7838 Q36534329-C85A2B47-F988-421C-B380-9A9DC2CBF1DA Q36545074-624E5FB5-8C54-4FF5-8369-1569A3A037FB Q37109246-C75F1DF9-72A3-421F-9A14-0A907393E0A6 Q37477267-7AE361B5-390E-435E-A923-631996374F1D Q37641257-BED83492-D72E-49C3-AA56-CCE549F99934 Q37680966-14B3E7F5-7967-47AB-885A-3C9BA0DA5EF5 Q37952240-E4BAF36E-839B-4532-8389-1FBFC2427A79 Q37952245-535CDAB3-2DFC-4003-8979-03104DEA6A77 Q37970682-A95FC6EA-0C95-4CBE-8505-2920EE62FE5B Q37980026-5C90C4D8-7B96-4AFA-BECE-99956DB590D4 Q38203815-A4F7E2B0-C83E-497E-8009-6756DF910058 Q38233114-6CAD33EA-D3B5-4613-8DB4-0FD050E17681 Q38245925-91460DEB-E0D6-434A-9D77-43A53517B2A0 Q38254629-5D5F193A-DCEA-4AA4-AFB3-231B37A72E8E Q38313826-EB3A81B8-19E3-418D-A454-ECA7B89E4E66 Q38358124-C085164E-D81B-4455-A8BC-C0DF1B4A0416 Q38362051-B1DB940C-F522-441C-81EA-7763DBC579BF Q38637324-F72C9A03-0CF6-4DE6-8DD1-ED6827615478 Q38743793-F11DE64F-68B0-4D22-9213-66872F0415B5 Q38829967-02EB90D8-7344-4A06-AF95-B085A39C4BCE Q38912265-2818B98D-E456-491C-924C-8EDDCB81489E Q39056846-E0AE8CFA-FA4B-4337-A892-6354424BF491 Q39198219-796FD850-2F85-4730-8FFB-7A35E623FFE4 Q39303777-E5128F0E-1E38-42A7-A586-1B53241C230A

P2860

Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

http://www.wikidata.org/entity/Q34480557

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Immunotherapy coming of age: w ...... dard of care for glioblastoma?

@ast

Immunotherapy coming of age: w ...... dard of care for glioblastoma?

@en

Immunotherapy coming of age: w ...... dard of care for glioblastoma?

@nl

type

label

Immunotherapy coming of age: w ...... dard of care for glioblastoma?

@ast

Immunotherapy coming of age: w ...... dard of care for glioblastoma?

@en

Immunotherapy coming of age: w ...... dard of care for glioblastoma?

@nl

prefLabel

Immunotherapy coming of age: w ...... dard of care for glioblastoma?

@ast

Immunotherapy coming of age: w ...... dard of care for glioblastoma?

@en

Immunotherapy coming of age: w ...... dard of care for glioblastoma?

@nl

P1433

Q34480557-B77CAC54-CCA2-4029-80C7-A1CD30853CC7

P1476

Q34480557-AFE1D8ED-CCD1-4276-9C79-2195F06704B9

P2093

Q34480557-85F574FA-400F-4A47-A187-15118642E0E8

Q34480557-FA088511-E85B-4CB4-80DD-76A8411677F7

P2860

Q34480557-0069EDFD-B4D9-42E6-B8B8-9A731CFF92FE

Q34480557-00DB3B89-0BC7-43D5-A2DC-4D1BA3FC6BEB

Q34480557-03662F4F-B620-4A7F-B346-4E45EE13C0E9

Q34480557-09648973-5CD0-4857-839A-0552191204F8

Q34480557-0C041567-B6B0-40CA-8E04-829C4F7C3848

Q34480557-0E81BCAA-0315-45D9-80F9-99F85B3D1EAA

Q34480557-13B79DF3-3D5C-47EA-AC19-A25AE2FEE596

Q34480557-17C08E14-83F8-43E7-BFD5-28266013AE26

Q34480557-1872D935-856A-449D-8791-1B569FBB90F7

Q34480557-1E179CB1-B480-4FA1-B058-7C5AF8E3F045

P304

Q34480557-D5ECEA73-9F64-4656-A7FA-9C99EC97F653

P31

Q34480557-76bc2a15-fe50-4c02-b157-51cd3b1a04f5

Q34480557-B9DEFA02-39D8-45F5-8865-9122AA12CA69

P356

Q34480557-F200D16C-A602-4D02-9483-2104EC47C605

P433

Q34480557-C8E2FDF2-C696-44DE-91E4-3AB3EC12A240

P478

Q34480557-A13A0115-5B27-4814-B6A5-5BEC11510A45

P577

Q34480557-E707BED1-A77C-4BEA-B27E-ED42059497AB

P5875

Q34480557-25C85806-CE29-4E7C-ABE3-759764E5834B

P698

Q34480557-C5E8EA2A-7FAC-4C29-984A-D81485D8FD85

P921

Q34480557-3528D15C-B1D3-451A-B2C0-DF1B3C6521BA

P932

Q34480557-EF4B60B7-A69D-48C0-8774-FF5715E9F043

P356

P1433

P1476

Immunotherapy coming of age: w ...... dard of care for glioblastoma?

@en

P2093

Amy B Heimberger

http://www.w3.org/2001/XMLSchema#string

John H Sampson

http://www.w3.org/2001/XMLSchema#string

P2860

Modulation of T-cell activation by malignant melanoma initiating cells

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

Phenotypic analysis of antigen-specific T lymphocytes

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Tumour-educated macrophages promote tumour progression and metastasis

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

P304

3-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOQ169

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49675089

http://www.w3.org/2001/XMLSchema#string

P698

21149252

http://www.w3.org/2001/XMLSchema#string

P921

P932

3018912

http://www.w3.org/2001/XMLSchema#string